Research programme: anti-CD55 antibodies - Genesis BiopharmaAlternative Names: Anti-CD55 antibody - Genesis Biopharma; Anti-DAF antibody - Genesis Biopharma; GBP-102; VG 102 - Genesis Biopharma
Latest Information Update: 24 May 2012
At a glance
- Originator Cancer Research Technology
- Developer Genesis Biopharma
- Class Antibodies
- Mechanism of Action CD55 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer; Lymphoma